SPORT High-Risk Trial Evaluating SABR in Prostate Cancer

Prostate Cancer Clinical Trial

— SPORT  

Official title:

A Randomised Feasibility Study Evaluating Stereotactic Prostate Radiotherapy In High-Risk Localised Prostate Cancer With or Without Elective Nodal Irradiation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03253978
• Other study ID #: 14190SJ-SS
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 18, 2016
• Est. completion date: April 30, 2026

Study information

• Verified date: September 2023
• Source: Belfast Health and Social Care Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will examine stereotactic ablative body radiotherapy (SABR), a new technique to deliver radiotherapy to men with prostate cancer. In addition to this, it will look at the effect of SABR on levels of markers of radiation exposure and bowel damage, along with other potential markers of outcome and side effects. Quality of life and any side effects that develop during and after treatment will also be assessed.

Description:

The study will examine stereotactic ablative body radiotherapy (SABR), a new technique to deliver radiotherapy to men with prostate cancer. In addition to this, it will look at the effect of SABR on levels of markers of radiation exposure and bowel damage, along with other potential markers of outcome and side effects. Quality of life and any side effects that develop during and after treatment will also be assessed. Participants will be treated with five treatments (instead of the standard 37). This is more convenient for them and also allows the treatment of many more people in the same time frame, which should improve the timely delivery of radiotherapy for all patients. Thirty men with high-risk prostate cancer will be enrolled into the study. They will all be treated with hormone therapy and radiotherapy to the prostate and seminal vesicles. In addition, half of the men will receive an additional dose of radiation to their pelvis. Gold markers will be placed in the prostate before radiotherapy to allow precise targeting of the prostate during treatment. CT scans are taken before and after each treatment to ensure the accuracy of its delivery. Blood urine and prostate tissue samples will be taken before, during and after radiotherapy. Side effects and quality of life will also by assessed during this time. Ultimately, this may allow us to predict which men are at increased risk of side effects from radiotherapy and allow closer monitoring, earlier intervention and perhaps alternative treatments in some cases. This should improve the control of prostate cancer and reduce the risk of serious treatment-related side effects

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients with histologically confirmed prostate adenocarcinoma who elect for radical

radiotherapy, with at least one of the following features:

• clinical stage T3a N0 M0
• Gleason score 7 (4+3) or above
• PSA > 20 No evidence of nodal or distant metastatic disease WHO performance status 0-2 Life expectancy of at least 5 years Men greater than or equal to 18 years Ability to understand and willingness to sign a written informed consent document (completed prior to registration and subsequent randomization), along with willingness to co-operate with follow-up Planned to receive 12-36 months of ADT as part of standard treatment Exclusion Criteria: T stage greater than or equal to T3b / T4 Prostate volume > 90cc

Current evidence of:

• inflammatory bowel disease or other chronic bowel disorder
• Autoimmune disease
• Active uncontrolled bacterial, viral or fungal infection
• Serious uncontrolled concomitant disease
• Known coagulopathy or bleeding diasthesis
• Anticoagulation medication (if unsafe to insert for seed insertion)
• Bilateral hip prosthesis or fixation which would interfere with standard radiation beam configuration
• Concurrent experimental or cytotoxic drugs
• Allergy to gold
• Severe lower urinary tract symptoms - International Prostate Symptom Score (IPSS) > 19
• Any other contra-indication to hormonal therapy or radical radiotherapy.

History of:

• Previous major abdominal surgery or history of bowel adhesions
• Prior pelvic radiotherapy
• Active malignancy within the preceding five years (other than basal cell carcinoma)

Evidence of:

• Castrate-resistance (rising PSA with castrate levels of testosterone on LHRHa and anti-androgen)

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Radiation:
• Stereotatic Radiotherapy
SABR to prostate / seminal nodes

Locations

Country	Name	City	State
United Kingdom	Belfast Health and Social Care Trust	Belfast	Co. Antrim

Sponsors (1)

Lead Sponsor	Collaborator
Belfast Health and Social Care Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adequate recruitment rate	adequate recruitment rate (30 patients in 24 months)	24 months
Primary	Acute toxicity of SABR	Acute toxicity of SABR (as assessed by CTCAE v4.03 scores until 90 days of completion of SABR)	90 days of completion of SABR
Primary	Acute quality of life during and after SABR	Acute quality of life during and after SABR (as assessed by EPIC and IPSS scores until 90 days after completion of SABR)	90 days after completion of SABR
Primary	Number of SABR plans delivered as planned and on schedule	Number of SABR plans delivered as planned and on schedule	29 days (treatment period)
Primary	Quantification of acute toxicity in each treatment group	Quantification of acute toxicity in each treatment group to enable calculation of the sample size for the Phase II RCT (using CTCAE v4.03 scores measured until 90days post completion of radiotherapy)	until 90 days post completion of radiotherapy
Secondary	Late toxicity of SABR	Late toxicity of SABR (as assessed by GI and GU RTOG late toxicity scores from 90 days to ten years post completion of SABR)	from 90 days and up to ten years post completion of SABR
Secondary	Late patient-reported quality of life	Late patient-reported quality of life (as assessed by EPIC and IPSS scores from 90 days to ten years post completion of SABR)	up to ten years post completion of SABR
Secondary	Rate of PSA failure	Rate of PSA failure as assessed by Phoenix criteria	up to ten years post completion of SABR
Secondary	Prostate cancer-specific survival	Prostate cancer-specific survival	up to ten years post completion of SABR
Secondary	Overall survival	Overall survival	up to ten years post completion of SABR